title: Molecular mechanisms of agonist-induced desensitization of the cloned mouse kappa opioid receptor.
abstract: Prolonged exposure of opioid receptors to agonists can cause desensitization, a cellular event linked to tolerance. Although evidence exists for mu and delta opioid receptor desensitization, much less information is available concerning the in vitro regulation of kappa opioid receptors because no cell lines exist that specifically express this class of opioid receptor. Recently we have cloned the mouse kappa opioid receptor. After expression in COS-7 cells, this protein exhibits the pharmacological specificity of a kappa 1 receptor and mediates agonist inhibition of cAMP formation. Continuous exposure of COS-7 cells expressing the kappa receptor to the agonist trans-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]- benzeneacetamide methanesulfonate salt (U50,488) reduces the specific binding of the kappa-selective agonist [3H]U69,593. Furthermore, the potency of U50,488 to inhibit the binding of the opiate antagonist [3H]naloxone to the kappa receptor is reduced. However, total specific binding of [3H]naloxone is not altered, indicating that short-term (2-4 hr) agonist treatment of the kappa receptor reduces the affinity of the receptor for agonists but does not reduce the density of kappa receptors. The reduction in affinity of the kappa receptor for agonists is dependent on the time of agonist exposure and is reversible. The reduced affinity of the receptor for agonists is associated with kappa receptor desensitization, because kappa receptor-mediated inhibition of cAMP formation is lost in cells pretreated with U50,488. The desensitization of the kappa receptor is dependent on the time and concentration of agonist treatment, is blocked by the kappa-selective antagonist nor-binaltorphimine and is reversible.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia.
authors.forename: K
authors.initials: K
authors.lastname: Raynor
authors.forename: H
authors.initials: H
authors.lastname: Kong
authors.forename: J
authors.initials: J
authors.lastname: Hines
authors.forename: G
authors.initials: G
authors.lastname: Kong
authors.forename: J
authors.initials: J
authors.lastname: Benovic
authors.forename: K
authors.initials: K
authors.lastname: Yasuda
authors.forename: G I
authors.initials: GI
authors.lastname: Bell
authors.forename: T
authors.initials: T
authors.lastname: Reisine
mesh_terms: D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000700:Analgesics / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D044482:Benzeneacetamides; D002417:Cattle; D002460:Cell Line; D003001:Cloning, Molecular; D017868:Cyclic AMP-Dependent Protein Kinases / Q000378:metabolism; D004361:Drug Tolerance; D051379:Mice; D011759:Pyrrolidines / Q000378:metabolism / Q000494:pharmacology*; D017473:Receptors, Opioid, kappa / Q000819:agonists* / Q000235:genetics; D011994:Recombinant Proteins; D051552:beta-Adrenergic Receptor Kinases
chemical_list: D000700:Analgesics; D044482:Benzeneacetamides; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D011994:Recombinant Proteins; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D017868:Cyclic AMP-Dependent Protein Kinases; D051552:beta-Adrenergic Receptor Kinases; C045444:U 69593